{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:42:44Z","timestamp":1792572164788,"version":"4.5.0"},"reference-count":33,"publisher":"American Chemical Society (ACS)","issue":"10","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100000082","name":"Division of Graduate Education","doi-asserted-by":"publisher","award":["2439861"],"award-info":[{"award-number":["2439861"]}],"id":[{"id":"10.13039\/100000082","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R15GM146193"],"award-info":[{"award-number":["R15GM146193"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Many clinically used chemotherapeutics, including doxorubicin, suffer from dose-limiting toxicities, poor biodistribution, and limited control over intracellular activation. To mitigate these challenges, two primary delivery strategies have been widely explored: prodrug design and liposomal encapsulation. Prodrugs can improve solubility, pharmacokinetics, and site-selective activation, while liposomes enhance circulation time and reduce off-target exposure. However, each approach presents limitations when employed independently. Prodrugs may introduce stability or solubility concerns and can undergo premature activation, whereas liposomal formulations often rely on passive release mechanisms and may exhibit incomplete or non-specific cargo leakage. In the current work, we sought to develop a synergistic delivery approach that integrates a chemically responsive prodrug directly within the liposomal membrane that responds to reactive oxygen species (ROS) highly upregulated within diseased cells. We report a ROS-responsive doxorubicin lipid prodrug conjugate, ROSDoxL, which is incorporated within the liposomal bilayer, enabling membrane-embedded therapeutic loading rather than aqueous core encapsulation. The prodrug design features a boronate caging group that undergoes oxidation in the presence of elevated reactive oxygen species, triggering a self-immolative release of doxorubicin. A non-responsive control doxorubicin lipid, DoxL, lacking the boronate moiety, was used to evaluate the specific ROS-mediated uncaging mechanism. ESI-HRMS studies confirmed ROS-dependent cleavage of ROSDoxL, while liposomal characterization and cellular studies demonstrated functional delivery and concentration-dependent cytotoxicity in A375 melanoma cells comparable to free doxorubicin. Our membrane-integrated liposomal prodrug approach provides a modular strategy for coupling disease-associated biochemical signals to controlled drug activation, advancing liposomal systems beyond passive carriers towards stimulus-responsive therapeutic delivery.<\/jats:p>","DOI":"10.1021\/acs.bioconjchem.6c00165","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:03:48Z","timestamp":1790021028000},"page":"1975-1986","source":"Crossref","is-referenced-by-count":0,"title":["A Synergistic Approach Using a ROS-Responsive Lipid-Based Prodrug for Liposomal Delivery of Doxorubicin"],"prefix":"10.1021","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4288-9173","authenticated-orcid":true,"given":"Brooke E.","family":"Smith","sequence":"first","affiliation":[{"name":"University of Tennessee , , , ,","place":["Knoxville, Tennessee, United States, 37996"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5064-761X","authenticated-orcid":true,"given":"Jinchao","family":"Lou","sequence":"additional","affiliation":[{"name":"University of Mississippi , , , ,","place":["University, Mississippi, United States, 38677"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda A.","family":"Phillips","sequence":"additional","affiliation":[{"name":"University of Tennessee , , , ,","place":["Knoxville, Tennessee, United States, 37996"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruhani","family":"Sagar","sequence":"additional","affiliation":[{"name":"University of Tennessee , , , ,","place":["Knoxville, Tennessee, United States, 37996"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Qualls","sequence":"additional","affiliation":[{"name":"University of Tennessee , , , ,","place":["Knoxville, Tennessee, United States, 37996"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9691-4290","authenticated-orcid":true,"given":"Dillon P.","family":"McBee","sequence":"additional","affiliation":[{"name":"University of Tennessee , , , ,","place":["Knoxville, Tennessee, United States, 37996"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Turner","sequence":"additional","affiliation":[{"name":"University of Tennessee , , , ,","place":["Knoxville, Tennessee, United States, 37996"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahbub","family":"Ullah","sequence":"additional","affiliation":[{"name":"University of Tennessee , , , ,","place":["Knoxville, Tennessee, United States, 37996"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4334-755X","authenticated-orcid":true,"given":"Joshua A.","family":"Baccile","sequence":"additional","affiliation":[{"name":"University of Tennessee , , , ,","place":["Knoxville, Tennessee, United States, 37996"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8737-5910","authenticated-orcid":true,"given":"Michael D.","family":"Best","sequence":"additional","affiliation":[{"name":"University of Tennessee , , , ,","place":["Knoxville, Tennessee, United States, 37996"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"issue":"6","key":"2026102103084519300_cit1","first-page":"670","article-title":"The Anthracyclines: Will We Ever Find a Better Doxorubicin?","volume":"19","author":"Weiss","year":"1992","journal-title":"Semin. Oncol."},{"issue":"6","key":"2026102103084519300_cit2","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/bit.260110607","article-title":"Adriamycin 14-Hydroxydaunomycin, a New Antitumor Antibiotic from S. Peucetius Var.Caesius","volume":"11","author":"Arcamone","year":"1969","journal-title":"Biotechnol. Bioeng."},{"issue":"2","key":"2026102103084519300_cit3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae--the First FDA-Approved Nano-Drug: Lessons Learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"issue":"1","key":"2026102103084519300_cit4","first-page":"35","article-title":"Molecular Biology of Doxorubicin-Induced Cardiomyopathy","volume":"7","author":"Umlauf","year":"2002","journal-title":"Exp. Clin. Cardiol."},{"issue":"25","key":"2026102103084519300_cit5","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.2174\/092986709788803312","article-title":"Doxorubicin: The Good, the Bad and the Ugly Effect","volume":"16","author":"Carvalho","year":"2009","journal-title":"Curr. Med. Chem."},{"issue":"10","key":"2026102103084519300_cit6","first-page":"3852","article-title":"Adriamycin-Activated Macrophages as Tumor Growth Inhibitors","volume":"41","author":"Haskill","year":"1981","journal-title":"Cancer Res"},{"issue":"3","key":"2026102103084519300_cit7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2183\/pjab.88.53","article-title":"Vascular Permeability in Cancer and Infection as Related to Macromolecular Drug Delivery, with Emphasis on the EPR Effect for Tumor-Selective Drug Targeting","volume":"88","author":"Maeda","year":"2012","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"2026102103084519300_cit8","unstructured":"Cell-Penetrating Peptides\ue5f8Mechanisms of Cellular Uptake and Generation of Delivery Systems-PMC. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4034016\/ (accessed Sep 08, 2023)."},{"issue":"1","key":"2026102103084519300_cit9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/critrevtherdrugcarriersyst.v25.i1.10","article-title":"Engineered Nanocarriers of Doxorubicin: A Current Update","volume":"25","author":"Patil","year":"2008","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"2026102103084519300_cit10","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.ejmech.2016.10.061","article-title":"Prodrug Approach: An Overview of Recent Cases","volume":"127","author":"Abet","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"2026102103084519300_cit11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1021\/acs.jmedchem.0c01704","article-title":"Reactive Oxygen Species (ROS)-Responsive Prodrugs, Probes, and Theranostic Prodrugs: Applications in the ROS-Related Diseases","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"4","key":"2026102103084519300_cit12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cmet.2011.03.010","article-title":"Unravelling the Biological Roles of Reactive Oxygen Species","volume":"13","author":"Murphy","year":"2011","journal-title":"Cell Metab"},{"issue":"52","key":"2026102103084519300_cit13","doi-asserted-by":"publisher","first-page":"2005918","DOI":"10.1002\/adfm.202005918","article-title":"ROS-Responsive Camptothecin Prodrug Nanoparticles for On-Demand Drug Release and Combination of Chemotherapy and Photodynamic Therapy","volume":"30","author":"Chu","year":"2020","journal-title":"Adv. Funct. Mater."},{"issue":"9","key":"2026102103084519300_cit14","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1021\/acs.molpharmaceut.3c00127","article-title":"ROS-Responsive Prodrug Micelle Co-Delivery System for Synergistic Antiatherosclerotic Therapy","volume":"20","author":"Tang","year":"2023","journal-title":"Mol. Pharm."},{"key":"2026102103084519300_cit15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/936486","article-title":"Reactive Oxygen Species in Health and Disease","author":"Alfadda","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"issue":"3","key":"2026102103084519300_cit16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1083\/jcb.200311055","article-title":"Oxidative Protein Folding in Eukaryotes : Mechanisms and Consequences","volume":"164","author":"Tu","year":"2004","journal-title":"J. Cell Biol."},{"issue":"5782","key":"2026102103084519300_cit17","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1126\/science.1130481","article-title":"H2O2, a Necessary Evil for Cell Signaling","volume":"312","author":"Rhee","year":"2006","journal-title":"Science"},{"issue":"3\u22124","key":"2026102103084519300_cit18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1089\/ars.2006.8.243","article-title":"Hydrogen Peroxide: A Signaling Messenger","volume":"8","author":"Stone","year":"2006","journal-title":"Antioxid. Redox Signal."},{"issue":"3","key":"2026102103084519300_cit19","first-page":"794","article-title":"Production of Large Amounts of Hydrogen Peroxide by Human Tumor Cells","volume":"51","author":"Szatrowski","year":"1991","journal-title":"Cancer Res"},{"issue":"1","key":"2026102103084519300_cit20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1021\/acs.bioconjchem.3c00476","article-title":"Cleavage and Noncleavage Chemistry in Reactive Oxygen Species (ROS)-Responsive Materials for Smart Drug Delivery","volume":"35","author":"Chi","year":"2024","journal-title":"Bioconjug. Chem."},{"issue":"33","key":"2026102103084519300_cit21","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1039\/C9TB00847K","article-title":"Reactive Oxygen Species (ROS)-Responsive Biomaterials Mediate Tissue Microenvironments and Tissue Regeneration","volume":"7","author":"Yao","year":"2019","journal-title":"J. Mater. Chem. B"},{"key":"2026102103084519300_cit22","doi-asserted-by":"publisher","first-page":"105990","DOI":"10.1016\/j.bioorg.2022.105990","article-title":"Modified Peroxamide-Based Reactive Oxygen Species (ROS)-Responsive Doxorubicin Prodrugs","volume":"127","author":"Jafari","year":"2022","journal-title":"Bioorganic Chem"},{"key":"2026102103084519300_cit23","doi-asserted-by":"publisher","first-page":"103158","DOI":"10.1016\/j.bioorg.2019.103158","article-title":"Arylboronate Prodrugs of Doxorubicin as Promising Chemotherapy for Pancreatic Cancer","volume":"91","author":"Skarbek","year":"2019","journal-title":"Bioorganic Chem"},{"issue":"28","key":"2026102103084519300_cit24","doi-asserted-by":"publisher","first-page":"7968","DOI":"10.1039\/C1CC12526E","article-title":"Investigation of Self-Immolative Linkers in the Design of Hydrogen Peroxide Activated Metalloprotein Inhibitors","volume":"47","author":"Jourden","year":"2011","journal-title":"Chem. Commun."},{"key":"2026102103084519300_cit25","doi-asserted-by":"publisher","first-page":"120791","DOI":"10.1016\/j.biomaterials.2021.120791","article-title":"Cancer-Activated Doxorubicin Prodrug Nanoparticles Induce Preferential Immune Response with Minimal Doxorubicin-Related Toxicity","volume":"272","author":"Yang","year":"2021","journal-title":"Biomaterials"},{"issue":"9","key":"2026102103084519300_cit26","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1007\/s11095-010-0183-x","article-title":"A Novel Doxorubicin Prodrug with Controllable Photolysis Activation for Cancer Chemotherapy","volume":"27","author":"Ibsen","year":"2010","journal-title":"Pharm. Res."},{"key":"2026102103084519300_cit27","doi-asserted-by":"publisher","first-page":"7875","DOI":"10.2147\/IJN.S335405","article-title":"TPGS2000-DOX Prodrug Micelles for Improving Breast Cancer Therapy","volume":"16","author":"Tang","year":"2021","journal-title":"Int. J. Nanomedicine"},{"key":"2026102103084519300_cit28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jconrel.2017.11.007","article-title":"Leakage Kinetics of the Liposomal Chemotherapeutic Agent Doxil: The Role of Dissolution, Protonation, and Passive Transport, and Implications for Mechanism of Action","volume":"269","author":"Russell","year":"2018","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"issue":"2","key":"2026102103084519300_cit29","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1021\/bc800414k","article-title":"Microplate-Based Analysis of Protein-Membrane Binding Interactions via Immobilization of Whole Liposomes Containing a Biotinylated Anchor","volume":"20","author":"Losey","year":"2009","journal-title":"Bioconjug. Chem."},{"issue":"8","key":"2026102103084519300_cit30","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.bbamem.2006.02.015","article-title":"Membrane Transport of Hydrogen Peroxide","volume":"1758","author":"Bienert","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"issue":"24","key":"2026102103084519300_cit31","doi-asserted-by":"publisher","first-page":"9371","DOI":"10.1021\/acs.orglett.1c03475","article-title":"Anodic Oxidation of Aminotetrazoles: A Mild and Safe Route to Isocyanides","volume":"23","author":"Leech","year":"2021","journal-title":"Org. Lett."},{"issue":"46","key":"2026102103084519300_cit32","doi-asserted-by":"publisher","DOI":"10.1002\/chem.202201057","article-title":"Reactive Oxygen Species (ROS) Activated Liposomal Cell Delivery Using a Boronate-Caged Guanidine Lipid","volume":"28","author":"Lou","year":"2022","journal-title":"Chem. Weinh. Bergstr. Ger."},{"issue":"17","key":"2026102103084519300_cit33","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1021\/ol0493094","article-title":"Polytriazoles as Copper(I)-Stabilizing Ligands in Catalysis","volume":"6","author":"Chan","year":"2004","journal-title":"Org. Lett."}],"container-title":["Bioconjugate Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.bioconjchem.6c00165","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/10\/1975\/68587410\/bc6c00165.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/10\/1975\/68587410\/bc6c00165.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:11:53Z","timestamp":1792570313000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/bcches\/article\/37\/10\/1975\/5434704\/A-Synergistic-Approach-Using-a-ROS-Responsive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,9,21]]},"published-print":{"date-parts":[[2026,10,21]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.bioconjchem.6c00165","relation":{},"ISSN":["1043-1802","1520-4812"],"issn-type":[{"value":"1043-1802","type":"print"},{"value":"1520-4812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]}}}